🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

788,80 EUR

Máx. histórico

912,40

61 días

Caída desde máximo

-13,55%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,61%

Cierre anterior

784,00

Rango de hoy

776,60 – 798,60

Volumen hoy

92.256

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,78%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
31,74 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.001,51 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
20/09/2024 481,70 483,40 477,80 482,00 -0,04% 1,16% 196.975
19/09/2024 475,70 484,10 472,40 482,20 +1,37% 2,46% 55.488
18/09/2024 471,90 476,70 460,00 475,70 -1,29% 3,54% 42.974
17/09/2024 485,50 488,80 480,60 481,90 -0,74% 1,69% 50.864
16/09/2024 485,60 493,10 483,50 485,50 -0,51% 1,98% 42.484
13/09/2024 486,00 488,70 482,70 488,00 +0,41% 1,23% 52.448
12/09/2024 486,20 489,00 483,60 486,00 -1,18% 1,11% 61.100
11/09/2024 482,00 493,10 478,90 491,80 +0,74% 2,95% 56.770
10/09/2024 497,30 500,80 488,20 488,20 -2,14% 2,53% 58.565
09/09/2024 487,60 500,40 486,30 498,90 +2,32% 2,89% 53.268
06/09/2024 488,00 493,60 484,70 487,60 +0,27% 1,82% 69.012
05/09/2024 469,50 488,10 467,00 486,30 +3,58% 4,49% 94.547
04/09/2024 458,10 469,90 457,00 469,50 +0,51% 2,82% 36.332
03/09/2024 464,80 469,70 462,70 467,10 +0,47% 1,51% 29.859
02/09/2024 468,00 468,50 462,90 464,90 -0,68% 1,20% 18.814
30/08/2024 470,40 472,80 464,20 468,10 -1,27% 1,83% 112.495
29/08/2024 466,80 474,10 465,70 474,10 +2,53% 1,80% 50.116
28/08/2024 461,30 466,70 461,30 462,40 +0,43% 1,17% 23.509
27/08/2024 465,50 466,50 459,80 460,40 -1,43% 1,44% 27.858
26/08/2024 464,10 468,80 463,80 467,10 +0,54% 1,08% 21.449
23/08/2024 467,00 473,70 464,40 464,60 -1,38% 1,99% 83.396
22/08/2024 471,80 478,10 470,50 471,10 -0,51% 1,61% 28.491
21/08/2024 471,70 479,40 471,40 473,50 +0,17% 1,70% 35.055
20/08/2024 474,30 479,60 472,50 472,70 -0,34% 1,50% 31.223
19/08/2024 475,20 478,70 470,10 474,30 -0,69% 1,81% 37.409
16/08/2024 479,90 483,00 475,30 477,60 -0,35% 1,60% 24.848
15/08/2024 477,60 483,80 474,70 479,30 +0,29% 1,91% 38.343
14/08/2024 480,40 486,60 470,80 477,90 -1,65% 3,29% 56.348
13/08/2024 488,50 490,50 481,80 485,90 -0,53% 1,78% 46.102
12/08/2024 485,20 492,80 484,90 488,50 +0,35% 1,63% 43.374